Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan P Graves

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|March 22, 2018
4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) InhibitorsJoanne Philp, Brian G Lawhorn, Alan P Graves, et al.
Journal of Medicinal Chemistry|October 26, 2021
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-RafJaclyn R Patterson, Alan P Graves, Patrick Stoy, et al.
ACS Medicinal Chemistry Letters|May 18, 2019
Discovery of GSK8612, a Highly Selective and Potent TBK1 InhibitorDouglas W Thomson, Daniel Poeckel, Nico Zinn, et al.
Structure (London, England : 1993)|April 13, 2016
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding PocketsGlenn S Van Aller, Alan P Graves, Patricia A Elkins, et al.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
SLAS Discovery : Advancing Life Sciences R & D|September 29, 2017
A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1Dean E McNulty, William G Bonnette, Hongwei Qi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with CancerChun-Fang Xu, Toby Johnson, Xiaojing Wang, et al.
Molecular Cancer Therapeutics|September 26, 2014
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylationHeidi M Ott, Alan P Graves, Melissa B Pappalardi, et al.
Journal of Medicinal Chemistry|September 11, 2015
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K)Brian G Lawhorn, Joanne Philp, Yongdong Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2012
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)Michael T McCabe, Alan P Graves, Gopinath Ganji, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|March 22, 2018
4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) InhibitorsJoanne Philp, Brian G Lawhorn, Alan P Graves, et al.
Journal of Medicinal Chemistry|October 26, 2021
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-RafJaclyn R Patterson, Alan P Graves, Patrick Stoy, et al.
ACS Medicinal Chemistry Letters|May 18, 2019
Discovery of GSK8612, a Highly Selective and Potent TBK1 InhibitorDouglas W Thomson, Daniel Poeckel, Nico Zinn, et al.
Structure (London, England : 1993)|April 13, 2016
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding PocketsGlenn S Van Aller, Alan P Graves, Patricia A Elkins, et al.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
SLAS Discovery : Advancing Life Sciences R & D|September 29, 2017
A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1Dean E McNulty, William G Bonnette, Hongwei Qi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with CancerChun-Fang Xu, Toby Johnson, Xiaojing Wang, et al.
Molecular Cancer Therapeutics|September 26, 2014
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylationHeidi M Ott, Alan P Graves, Melissa B Pappalardi, et al.
Journal of Medicinal Chemistry|September 11, 2015
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K)Brian G Lawhorn, Joanne Philp, Yongdong Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2012
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)Michael T McCabe, Alan P Graves, Gopinath Ganji, et al.
Pageof 3